Triastek and Siemens announce strategic collaboration to accelerate the digital transformation of the pharmaceutical industry


Regulatory agencies, including the US FDA (Food and Drug Administration), European EMA (European Medicines Agency) and China The National Medical Products Administration (NMPA) has encouraged pharmaceutical companies to modernize their manufacturing processes by adopting continuous manufacturing processes and digital technologies. Triastek actively implements the continuous manufacturing approach in conjunction with advanced digital tools to streamline and improve its manufacturing processes and products. Combining these innovations with Siemens’ expertise in digitalization and automation will meet regulators’ desires to reduce pharmaceutical product quality issues, reduce manufacturing costs and improve drug availability. quality for patients.

This collaboration between Triastek and Siemens will leverage their respective advantages, strengths and technological capabilities to meet the needs of the pharmaceutical industry and improve patient outcomes. Triastek’s exclusive pharmaceutical MED® (Melt Extrusion Deposition) 3D printing platform technology for R&D and mass production integrated with advanced automation and digital technologies provided by Siemens will accelerate product R&D and facilitate continuous manufacturing approaches, paperless production, real-time product release, maintenance of equipment and facilities. These innovations are expected to improve production line throughput while maintaining the highest product quality.

Finally, in collaboration with Siemens, Triastek plans to establish a smart pharmaceutical manufacturing center, where a virtual laboratory, smart factory and digital twin technologies will be integrated into all aspects of pharmaceutical operations.

Founded in 2015, Triastek has entered the stage of mass production and commercial development. In October 2021Triastek released its Era 2.0 Open Strategy, a plan to market its proprietary MED® 3D printing technology through collaboration with pharmaceutical companies and global suppliers. Based on its open strategy and collaboration, Triastek provides digital product R&D and an innovative manufacturing platform that enables business partners to use and integrate Triastek technologies into their operations, from initial development of drugs to commercial production.

dr. Senping Chengfounder and CEO of Triastek, commented on the announcement: “This strategic collaboration has expanded the possibilities of pharmaceutical digitization. Triastek’s MED® 3D printing technology represents a new digital pharmaceutical technology, laying the foundation for a digital pharmaceutical future. MEDIUM® 3D printing represents a new drug R&D paradigm, from product development to product launch, while introducing new models to manage production and supply. Triastek will make this open platform available to digital technology providers to jointly advance the Pharma 4.0 initiative, in service of our broader vision to transform the future of the pharmaceutical industry. »

Sir. Jinsong ZhangSenior Vice President and General Manager of Digital Industries East Sales Region of Siemens Ltd., China also commented on this partnership: “Siemens’ strategic cooperation with Triastek builds a win-win cooperation between a leader in digital solution providers and a pharmaceutical leader in 3D printing. Siemens has a wealth of experience in 3D printing and a full suite of digital solutions for manufacturing transformation. believe that merging 3D printing technology with pharmaceutical scanning establishes a new paradigm, which unifies R&D and manufacturing, and advances the end-to-end model from demand to delivery. The partnership will help Triastek accelerate digital pharmaceuticals 4.0, which will ultimately bring about significant benefits for the pharmaceutical industry worldwide.”

SOURCE Triastek, Inc.


Comments are closed.